It seems like just yesterday that Dexcom, Insulet and Tandem were three of the hottest stocks on the NASDAQ. Yet over the last three months all three have been hit hard, with the NASDAQ down over 21% over that span these three stocks have fallen more than that with Insulet getting hit hardest falling almost 29%. Now we could mention that trading at $108 per share Dexcom is still well into the money since we noted it was a good time to buy when the stock was trading near $60.
So, do we chalk up this recent slide as normal . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.